Andere Sprachen KalVista Pharmaceuticals, Inc.

Aktien

A2DG49

US4834971032

KALV

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:16:59 26.04.2024			% 5 Tage	% 1. Jan.
10.77 ^USD	+2.67%		-6.91%	-12.08%

22.04.	Kalvista Pharmaceuticals, Inc. ernennt William C. Fairey zum Mitglied des Board of Directors	CI
18.03.	KalVista Pharmaceuticals präsentiert auf der HAEi Regional Conference Americas 2024 reale Daten zur Belastung durch die Behandlung und zur Dauer der HAE-Attacke	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors	22.04.
Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors	22.04.
Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15.04.
Certain performance stock options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15.04.
Certain restricted stock units of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15.04.
Certain Stock Options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15.04.
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	03.04.
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference	03.04.
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02.04.
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	18.03.
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	18.03.
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine Designation for Sebetralstat	13.03.
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat	12.03.
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	11.03.
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update	11.03.
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	08.03.
KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	08.03.
KalVista Pharmaceuticals Names Benjamin Palleiko as CEO	07.03.
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer	07.03.
KalVista Pharmaceuticals, Inc. Announces Board Changes	07.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen KalVista Pharmaceuticals, Inc.

Aktien

A2DG49

US4834971032

KALV

Andere Sprachen

Filter